SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants

Z-X Cao ,  J-J Liu ,  R-L Zheng ,  J Yang ,  L Zhong ,  Y Xu ,  L-J Wang ,  C-H Zhang ,  B-L Wang ,  S Ma ,  Z-R Wang ,  H-Z Xie ,  Y-Q Wei ,  S-Y Yang